Tag: her2-negative breast cancer market share

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

How Much Larger Is The HER2-Negative Breast Cancer Market Expected To Become By 2029 Compared With Its 2025 Level?

The her2-negative breast cancer market has seen substantial expansion in recent years. It is anticipated to expand from $16.29 billion in 2024 to $17.57 billion in 2025, achieving a compound annual growth rate (CAGR) of 7.8%. This historical growth can be attributed to factors such as an escalation in breast cancer instances, enhanced understanding of breast cancer, augmented healthcare spending, an aging demographic, and the development of healthcare infrastructure.

The her2-negative breast cancer market size is anticipated to undergo significant expansion in the upcoming years, with projections indicating it will reach $23.67 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 7.7%. This expansion during the forecast period can be ascribed to a number of factors, including the increasing intake of alcohol, the rising adoption of unhealthy lifestyle choices, the growing prevalence of obesity, increased tobacco consumption, and the heightened necessity for effective therapeutic solutions. Dominant trends expected during this period involve advancements in diagnostic technologies, the incorporation of targeted therapies, the integration of immunotherapies, FDA regulatory approvals, and general technological progress.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21203&type=smp

Which Industry Drivers Are Expected To Accelerate The HER2-Negative Breast Cancer Market From 2025 To 2029?

The anticipated rise in breast cancer occurrences is expected to drive the expansion of the HER2-negative breast cancer market. Breast cancer is a condition characterized by the uncontrolled proliferation of abnormal cells within breast tissue, typically originating in the ducts or lobules. This increase in incidence can be attributed to several factors, including enhanced public awareness and improved screening techniques, which lead to earlier and more frequent detection. HER2-Negative Breast Cancer is crucial for advancing breast cancer research, offering valuable insights into distinct tumor biology and treatment strategies, thereby contributing to the development of more targeted therapies for patients. For instance, the Centers for Disease Control and Prevention, a US-based government agency, reported in June 2024 that in the United States, 272,454 new cases of breast cancer were diagnosed among females in 2021, while 42,211 females succumbed to the disease in 2022. Thus, the increasing incidence of breast cancer cases is a primary driver for the growth of the HER2-negative breast cancer market.

Which Key Segments Fueling The HER2-Negative Breast Cancer Market?

The her2-negative breast cancermarket covered in this report is segmented –

1) By Treatment Type: Chemotherapy; Hormone Therapy; Targeted Therapy; Immunotherapy

2) By Cancer Stage: Early Stage; Locally Advanced Stage; Metastatic Stage

3) By Distribution Channel: Hospital Pharmacy; Retail Pharmacy; Online Pharmacy

Subsegments:

1) By Chemotherapy: Anthracyclines; Taxanes; Platinum-Based Chemotherapy; Alkylating Agents; Antimetabolites

2) By Hormone Therapy: Selective Estrogen Receptor Modulators (SERMs); Aromatase Inhibitors; Selective Estrogen Receptor Degraders (SERDs)

3) By Targeted Therapy: CDK4/6 Inhibitors; PI3K Inhibitors; PARP Inhibitors

4) By Immunotherapy: Immune Checkpoint Inhibitors; Tumor-Infiltrating Lymphocyte (TIL) Therapy

Which Competitive Trends Are Defining The HER2-Negative Breast Cancer Market Structure?

Leading companies active in the HER2-negative breast cancer market are concentrating on obtaining regulatory authorizations to introduce new therapies, expand their product offerings, and strengthen their presence. Regulatory approvals denote the formal permission provided by government bodies, allowing firms to market and distribute drugs or treatments after fulfilling safety, efficacy, and quality criteria. For example, in October 2024, Genentech Inc., a US-based biotechnology corporation, secured FDA approval for Itovebi (inavolisib) as a targeted therapy for advanced hormone receptor-positive (HR+), HER2-negative breast cancer with a PIK3CA mutation. This clearance enables Itovebi to be utilized in conjunction with palbociclib and fulvestrant, substantially enhancing progression-free survival for patients compared to existing standard treatments. This new approach offers a crucial choice for patients with limited therapeutic options, underscoring the significance of biomarker testing to identify those who would most benefit from this particular therapy.

Which Key Market Players Are Investing In Expansion And Innovation Of HER2-Negative Breast Cancer Market?

Major companies operating in the HER2-negative breast cancer market are Pfizer Inc., Merck & Co. Inc., AbbVie Inc., Bayer AG, Bristol-Myers Squibb Company, Sanofi S.A., AstraZeneca PLC, Novartis International AG, Eli Lilly and Company, Amgen Inc., Daiichi Sankyo Company Limited, Jiangsu Hansoh Pharmaceutical Co. Ltd., BeiGene Ltd., Chipscreen Biosciences Ltd., F. Hoffmann-La Roche Ltd, PharmAbcine Inc., Adagene Inc., H3 Biomedicine Inc., Radius Health Inc., Zenith Epigenetics Ltd.

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/her2-negative-breast-cancer-global-market-report

How Do Regional Market Performances Compare Within The HER2-Negative Breast Cancer Industry?

North America was the largest region in the HER2-negative breast cancer market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the HER2-negative breast cancer market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Version Of The HER2-Negative Breast Cancer Market Report:

https://www.thebusinessresearchcompany.com/customise?id=21203&type=smp

Browse Through More Reports Similar to the Global HER2-Negative Breast Cancer Market 2025, By The Business Research Company

Breast Implants Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/breast-implants-global-market-report

Breast Pumps Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/breast-pumps-global-market-report

Breast Imaging Technologies Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/breast-imaging-technologies-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Is the Forecast for the HER2-Negative Breast Cancer Market Growth in 2025?

The market for HER2-negative breast cancer has been enjoying robust growth in recent years. It is forecasted to rise from $16.29 billion in 2024 to $17.62 billion in 2025, representing an impressive compound annual growth rate (CAGR) of 8.1%. The development experienced in the historic period can be linked to the increase in incidences of breast cancer, elevated awareness concerning the disease, heightened expenditure on healthcare, an aging demographic, and the growth of healthcare infrastructures.

What Is the Forecast for the HER2-Negative Breast Cancer Market Size Through 2029?

The market size of HER2-negative breast cancer is anticipated to witness robust growth in the upcoming years. The industry is projected to expand to $23.86 billion by 2029, with a compound annual growth rate (CAGR) of 7.9%. Various factors contributing to this projected growth through the forecast period include the upsurge in alcohol consumption, a rise in unhealthy lifestyle choices, escalating obesity rates, an increase in tobacco use, and the escalating demand for effective treatment solutions. Notable trends expected to shape the market throughout the forecast period encompass advancements in diagnostic technologies, the incorporation of targeted therapies, the amalgamation of immunotherapies, approvals from FDA, and technological progress.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21203&type=smp

What are the Key Market Players in HER2-Negative Breast Cancer Market and How They’re Evolving?

Major companies operating in the HER2-negative breast cancer market are Pfizer Inc., Merck & Co. Inc., AbbVie Inc., Bayer AG, Bristol-Myers Squibb Company, Sanofi S.A., AstraZeneca PLC, Novartis International AG, Eli Lilly and Company, Amgen Inc., Daiichi Sankyo Company Limited, Jiangsu Hansoh Pharmaceutical Co. Ltd., BeiGene Ltd., Chipscreen Biosciences Ltd., F. Hoffmann-La Roche Ltd, PharmAbcine Inc., Adagene Inc., H3 Biomedicine Inc., Radius Health Inc., Zenith Epigenetics Ltd.

What Are the Primary Growth Drivers in the HER2-Negative Breast Cancer Market?

The increasing number of breast cancer incidents is anticipated to boost the expansion of the HER2-negative breast cancer market in the future. Breast cancer, a condition characterized by the unchecked expansion of abnormal cells in breast tissue, typically originates from the ducts or lobules. The increasing number of breast cancer incidents can be linked to numerous elements, including heightened awareness and improved screening techniques, resulting in earlier and more consistent detection. HER2-Negative Breast Cancer plays a pivotal role in propelling breast cancer research by offering insights into unique tumor biology and treatment strategies, thereby aiding in the creation of more targeted remedies for patients. For instance, the Centers for Disease Control and Prevention, a US government agency, reported that, in the United States in June 2024, 272,454 new breast cancer cases were identified among women in 2021, while 42,211 women died from the disease in 2022. Consequently, the increasing number of breast cancer incidents is stimulating the expansion of the HER2-negative breast cancer market.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=21203&type=smp

What Are the Leading Segments in the Global HER2-Negative Breast Cancer Industry?

The HER2-negative breast cancer market covered in this report is segmented –

1) By Treatment Type: Chemotherapy, Hormone Therapy, Targeted Therapy, Immunotherapy

2) By Cancer Stage: Early Stage, Locally Advanced Stage, Metastatic Stage

3) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy

Subsegments:

1) By Chemotherapy: Anthracyclines, Taxanes, Platinum-Based Chemotherapy, Alkylating Agents, Antimetabolites

2) By Hormone Therapy: Selective Estrogen Receptor Modulators (SERMs), Aromatase Inhibitors, Selective Estrogen Receptor Degraders (SERDs)

3) By Targeted Therapy: CDK4/6 Inhibitors, PI3K Inhibitors, PARP Inhibitors

4) By Immunotherapy: Immune Checkpoint Inhibitors, Tumor-Infiltrating Lymphocyte (TIL) Therapy

What Are the Key Market Trends in the HER2-Negative Breast Cancer Industry?

Prominent entities in the HER2-negative breast cancer market are concentrating on obtaining regulatory clearances to launch fresh treatments, broaden their product range, and upgrade their market stature. Regulatory approval implies the formal permission provided by government authorities, which permits companies to sell and disperse drugs or treatments upon fulfilling safety, efficacy, and quality criteria. For instance, in October 2024, Genentech Inc., a US-based biotech company, achieved FDA authorization for Itovebi (inavolisib), a focused treatment for advanced HR+, HER2-negative breast cancer with a PIK3CA mutation. This approval authorizes the use of Itovebi along with palbociclib and fulvestrant, thereby significantly ameliorating progression-free survival for patients as compared to traditional treatments. This novel regimen offers a crucial alternative for patients with bounded treatment options, underlining the significance of biomarker testing to pinpoint those who would benefit the most from this treatment.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/her2-negative-breast-cancer-global-market-report

What Is the Regional Outlook for the HER2-Negative Breast Cancer Market?

North America was the largest region in the HER2-negative breast cancer market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the HER2-negative breast cancer market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21203

This Report Delivers Insight On:

1. How big is the her2-negative breast cancer market, and how is it changing globally?

2. Who are the major companies in the her2-negative breast cancer market, and how are they performing?

3. What are the key opportunities and risks in the her2-negative breast cancer market right now?

4. Which products or customer segments are growing the most in the her2-negative breast cancer market?

5. What factors are helping or slowing down the growth of the her2-negative breast cancer market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 2071930708

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Our market reports now include the latest updates on global tariffs, trade impacts, and evolving supply chain dynamics.

What Is the Current and Projected Market Size of the HER2-Negative Breast Cancer Market Through 2034?

The market size for HER2-negative breast cancer has witnessed significant growth over the past few years. It is projected to rise from $16.29 billion in 2024 to $17.62 billion in 2025, registering a compound annual growth rate (CAGR) of 8.1%. Factors contributing to this surge during the historic period include a rise in breast cancer incidences, a greater understanding of breast cancer, heightened healthcare expenditure, an increasing aging population, and growth in healthcare facilities.

There is an expectation of significant expansion in the market size for HER2-negative breast cancer in the upcoming years. By 2029, the market is projected to reach $23.86 billion, with a compound annual growth rate (CAGR) of 7.9%. This predicted surge in the forecast period can be credited to factors such as rising levels of alcohol and tobacco use, escalation in adoption of detrimental lifestyle habits, augmented incidence of obesity, and a mounting need for efficient treatment methodologies. The forecast period is also likely to witness major trends such as advancements in diagnostic technologies, the introduction of target-specific therapies, the incorporation of immunotherapies, FDA validations, and breakthroughs in technology.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21203&type=smp

How Are Key Drivers in the Industry Acting as Catalysts for the Growth of the HER2-Negative Breast Cancer Market?

The surge in incidences of breast cancer is projected to fuel the expansion of the HER2-negative breast cancer market. Breast cancer, typified by erratic growth of abnormal cells in the breast tissue, often originating from the ducts or lobules, is becoming more prevalent. The escalation in breast cancer cases is attributable to several aspects, including heightened awareness and advancements in screening methods, resulting in more common and earlier detection. The vital role that HER2-negative breast cancer plays in expediting breast cancer research through insights into diverse tumor biology and treatment approaches significantly aids the development of more personalized therapies for patients. For instance, data from the Centers for Disease Control and Prevention, a US-based public agency, indicated that there were 272,454 newly diagnosed breast cancer cases among females in 2021 and 42,211 female deaths in 2022 in the United States. Consequently, the surge in breast cancer incidence serves as the drive behind the growth of the HER2-negative breast cancer market.

Which Segments in the HER2-Negative Breast Cancer Offer the Most Growth?

The HER2-negative breast cancer market covered in this report is segmented –

1) By Treatment Type: Chemotherapy, Hormone Therapy, Targeted Therapy, Immunotherapy

2) By Cancer Stage: Early Stage, Locally Advanced Stage, Metastatic Stage

3) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy

Subsegments:

1) By Chemotherapy: Anthracyclines, Taxanes, Platinum-Based Chemotherapy, Alkylating Agents, Antimetabolites

2) By Hormone Therapy: Selective Estrogen Receptor Modulators (SERMs), Aromatase Inhibitors, Selective Estrogen Receptor Degraders (SERDs)

3) By Targeted Therapy: CDK4/6 Inhibitors, PI3K Inhibitors, PARP Inhibitors

4) By Immunotherapy: Immune Checkpoint Inhibitors, Tumor-Infiltrating Lymphocyte (TIL) Therapy

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=21203&type=smp

What Are the Fastest-Growing Geographies in the How Are Key Drivers in the Industry Acting as Catalysts for the Growth of the HER2-Negative Breast Cancer Market? Market?

North America was the largest region in the HER2-negative breast cancer market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the HER2-negative breast cancer market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

What Are the Current Market Growth and Trends in the HER2-Negative Breast Cancer Industry?

Major firms active in the HER2-negative breast cancer market are striving to secure regulatory consent to launch fresh treatment methods, broaden their product lines, and increase their market visibility. Regulatory consent is the formal permission given by government bodies that enables firms to sell and distribute medications or treatments after they have satisfied safety, efficacy, and quality criteria. For instance, in October 2024, Genentech Inc., a biotechnology firm based in the United States, secured FDA clearance for Itovebi (inavolisib), aimed at treating advanced hormone receptor-positive (HR+), HER2-negative breast cancer with a PIK3CA mutation. This permission permits the use of Itovebi together with palbociclib and fulvestrant, markedly enhancing the progression-free survival of patients in contrast to traditional treatments. This novel regimen offers a crucial alternative for patients with limited therapy options, underlining the significance of biomarker testing in determining those who would reap the greatest benefit from this treatment.

View the full report here:

https://www.thebusinessresearchcompany.com/report/her2-negative-breast-cancer-global-market-report

What Are the Key Elements That Define the HER2-Negative Breast Cancer Market?

HER2-negative breast cancer refers to a type of breast cancer where the cancer cells do not have high levels of the HER2 protein, which promotes tumour growth. This type of cancer tends to grow more slowly than HER2-positive breast cancer and is treated with targeted therapies and chemotherapy.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21203

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

2025 Market Reports Update: Market Size Forecasts to 2034, Key Trends, Leading Players, and Top Regions – Get Ahead of the Competition Today!

How Are Key Drivers in the Industry Acting as Catalysts for the Growth of theHER2-Negative Breast Cancer Market?

The increasing incidence of breast cancer is expected to drive the growth of the HER2-negative breast cancer market in the coming years. Breast cancer is characterized by the uncontrolled growth of abnormal cells in the breast, often originating in the ducts or lobules. Contributing factors to the rising incidence of breast cancer include greater awareness and enhanced screening methods, which lead to earlier and more frequent detection. HER2-negative breast cancer plays a significant role in advancing research into breast cancer by providing insights into tumor biology and treatment strategies, thereby aiding the development of more targeted therapies. For example, the Centers for Disease Control and Prevention reported in June 2024 that in 2021, 272,454 new cases of breast cancer were diagnosed in U.S. females, and in 2022, 42,211 females died from the disease. Consequently, the growing incidence of breast cancer is driving the growth of the HER2-negative breast cancer market.

Get Your Free Sample Report Now – Explore Exclusive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21203&type=smp

#What Growth Opportunities Will Drive the HER2-Negative Breast Cancer Market’s CAGR Through 2034?

The HER2-negative breast cancer market has grown strongly, rising from $16.29 billion in 2024 to $17.62 billion in 2025 at a CAGR of 8.1%. Key growth drivers include the increasing prevalence of breast cancer, heightened awareness, rising healthcare spending, an aging population, and improved healthcare infrastructure.

The HER2-negative breast cancer market size is expected to witness substantial growth in the coming years, reaching $23.86 billion by 2029 at a CAGR of 7.9%. The market expansion is driven by increased alcohol consumption, a growing trend of unhealthy lifestyles, rising obesity rates, a surge in tobacco usage, and an increasing demand for effective treatment solutions. Key trends anticipated include advancements in diagnostic technologies, integration of targeted therapies, growing adoption of immunotherapies, FDA approvals, and continuous technological advancements.

You can Directly Purchase the Report Here:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21203

What Are the Current Market Growth and Trends in theHER2-Negative Breast Cancer Market That Industry Players Should Watch?

In the HER2-negative breast cancer market, companies are focusing on securing regulatory approvals to expand their product portfolios and enhance their market presence. Regulatory approvals are granted by agencies like the FDA once a drug meets safety, efficacy, and quality standards. In October 2024, Genentech Inc., a US-based biotechnology corporation, received FDA approval for Itovebi (inavolisib), a targeted treatment for advanced hormone receptor-positive (HR+), HER2-negative breast cancer with a PIK3CA mutation. This approval allows Itovebi to be used in combination with palbociclib and fulvestrant, improving progression-free survival for patients compared to standard treatments.

What Are the Major Market Players Making an Impact on theHER2-Negative Breast Cancer Market Growth?

Major companies operating in the HER2-negative breast cancer market are Pfizer Inc., Merck & Co. Inc., AbbVie Inc., Bayer AG, Bristol-Myers Squibb Company, Sanofi S.A., AstraZeneca PLC, Novartis International AG, Eli Lilly and Company, Amgen Inc., Daiichi Sankyo Company Limited, Jiangsu Hansoh Pharmaceutical Co. Ltd., BeiGene Ltd., Chipscreen Biosciences Ltd., F. Hoffmann-La Roche Ltd, PharmAbcine Inc., Adagene Inc., H3 Biomedicine Inc., Radius Health Inc., Zenith Epigenetics Ltd.

Order Your Report Now For A Swift Delivery:

https://www.thebusinessresearchcompany.com/report/her2-negative-breast-cancer-global-market-report

How Are the Key Segments of the HER2-Negative Breast Cancer Market Driving Opportunities and Innovations?

The HER2-negative breast cancer market covered in this report is segmented –

1) By Treatment Type: Chemotherapy, Hormone Therapy, Targeted Therapy, Immunotherapy

2) By Cancer Stage: Early Stage, Locally Advanced Stage, Metastatic Stage

3) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy

Subsegments:

1) By Chemotherapy: Anthracyclines, Taxanes, Platinum-Based Chemotherapy, Alkylating Agents, Antimetabolites

2) By Hormone Therapy: Selective Estrogen Receptor Modulators (SERMs), Aromatase Inhibitors, Selective Estrogen Receptor Degraders (SERDs)

3) By Targeted Therapy: CDK4/6 Inhibitors, PI3K Inhibitors, PARP Inhibitors

4) By Immunotherapy: Immune Checkpoint Inhibitors, Tumor-Infiltrating Lymphocyte (TIL) Therapy

Gain Exclusive Market Insights—Customize Your Research Report Today for Fast Delivery!

https://www.thebusinessresearchcompany.com/customise?id=21203&type=smp

What Regions Are At the Forefront of #How Are Key Drivers in the Industry Acting as Catalysts for the Growth of theHER2-Negative Breast Cancer Market?# Market Expansion?

North America was the largest region in the HER2-negative breast cancer market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the HER2-negative breast cancer market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Browse Through More Reports Similar to the Global HER2-Negative Breast Cancer Market 2025, By The Business Research Company:

Anemia and Other Blood Disorder Drugs Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/anemia-and-other-blood-disorder-drugs-global-market-report

Blood Cancer Drugs Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/blood-cancer-drugs-global-market-report

Lateral Flow Immunoassay (LFIA) Based Rapid Test Global Market Report 2025

https://thebusinessresearchcompany.com/report/lateral-flow-immunoassay-based-rapid-test-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on:

Get 20% off on Global Market Reports until March 31st! Use code FY25SAVE at checkout.

How has the her2-negative breast cancer market size evolved in recent years?

The market size for HER2-negative breast cancer has seen significant growth in recent years. Projected growth for this sector is from $16.29 billion in 2024 to $17.62 billion in 2025, at a compound annual growth rate (CAGR) of 8.1%. Factors contributing to the growth during the historic period include a surge in breast cancer diagnoses, heightened awareness concerning breast cancer, elevated healthcare expenditure, an aging population, and improvements to healthcare facilities.

What are the predictions for the her2-negative breast cancer market size in the coming years?

We anticipate robust expansion in the HER2-negative breast cancer market over the coming years. The market is projected to reach a value of $23.86 billion by 2029, with a compound annual growth rate (CAGR) of 7.9%. Factors influencing this growth during the forecast period may include heightened alcohol consumption, adoption of poor lifestyle choices, an uptick in obesity prevalence, increased tobacco use, and a growing demand for effective treatment methods. Expected trends for the forecast period are advances in diagnostic technology, the introduction of targeted therapies, the inclusion of immunotherapies, approvals by the FDA, and technological advancements.

Get your her2-negative breast cancer market report here!

https://www.thebusinessresearchcompany.com/report/her2-negative-breast-cancer-global-market-report

What key factors are fueling the growth of the her2-negative breast cancer market?

The increasing instances of breast cancer are anticipated to drive the progress of the HER2-negative breast cancer market. Breast cancer manifests as uncontrolled proliferation of abnormal cells in the breast tissue, typically originating from the ducts or lobules. The growth in breast cancer instances can be linked to factors such as heightened awareness and enhanced screening practices, resulting in earlier and more regular detection. HER2-Negative Breast Cancer contributes significantly to breast cancer research by offering valuable information on distinctive tumor biology and treatment strategies, aiding the creation of more patient-specific therapies. For example, The Centers for Disease Control and Prevention, a governmental agency in the U.S., reported 272,454 fresh cases of breast cancer in females in 2021, with 42,211 females passing away from the disease in 2022. This surge in breast cancer incidences is thus propelling the HER2-negative breast cancer market forward.

How is the global her2-negative breast cancer market divided into key segments?

The HER2-negative breast cancer market covered in this report is segmented –

1) By Treatment Type: Chemotherapy, Hormone Therapy, Targeted Therapy, Immunotherapy

2) By Cancer Stage: Early Stage, Locally Advanced Stage, Metastatic Stage

3) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy

Subsegments:

1) By Chemotherapy: Anthracyclines, Taxanes, Platinum-Based Chemotherapy, Alkylating Agents, Antimetabolites

2) By Hormone Therapy: Selective Estrogen Receptor Modulators (SERMs), Aromatase Inhibitors, Selective Estrogen Receptor Degraders (SERDs)

3) By Targeted Therapy: CDK4/6 Inhibitors, PI3K Inhibitors, PARP Inhibitors

4) By Immunotherapy: Immune Checkpoint Inhibitors, Tumor-Infiltrating Lymphocyte (TIL) Therapy

Get your free sample now – explore exclusive market insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21203&type=smp

Who are the key firms paving the way for growth in the her2-negative breast cancer market?

Major companies operating in the HER2-negative breast cancer market are Pfizer Inc., Merck & Co. Inc., AbbVie Inc., Bayer AG, Bristol-Myers Squibb Company, Sanofi S.A., AstraZeneca PLC, Novartis International AG, Eli Lilly and Company, Amgen Inc., Daiichi Sankyo Company Limited, Jiangsu Hansoh Pharmaceutical Co. Ltd., BeiGene Ltd., Chipscreen Biosciences Ltd., F. Hoffmann-La Roche Ltd, PharmAbcine Inc., Adagene Inc., H3 Biomedicine Inc., Radius Health Inc., Zenith Epigenetics Ltd.

What key trends are currently impacting the her2-negative breast cancer market’s development?

Leading corporations within the HER2-negative breast cancer sector are concentrating on securing requisite permits to roll out new therapies, broaden their product array, and boost their standing within the market. These permits are formal permissions provided by government bodies that enable companies to distribute and advertise their medications or treatments once safety, efficiency, and quality criteria are satisfied. For instance, Genentech Inc., a prominent US biotech firm, in October 2024, obtained FDA clearance to sell Itovebi (inavolisib). This groundbreaking therapy targets advanced hormone receptor-positive (HR+), HER2-negative breast cancer with a PIK3CA mutation. Aside from fulfilling FDA criteria, this endorsement allows Itovebi to be combined with palbociclib and fulvestrant, demonstrating a marked enhancement in progression-free survival in patients vis-a-vis standard medications. This innovative treatment regimen underscores the importance of biomarker tests, as this allows for identifying and providing the best treatment options for patients who have limited options.

Unlock exclusive market insights – purchase your research report now for a swift delivery!

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21203

What regions are contributing significantly to the growth of the her2-negative breast cancer market?

North America was the largest region in the HER2-negative breast cancer market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the HER2-negative breast cancer market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Browse Through More Similar Reports By The Business Research Company:

Anemia and Other Blood Disorder Drugs Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/anemia-and-other-blood-disorder-drugs-global-market-report

Blood Cancer Drugs Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/blood-cancer-drugs-global-market-report

Lateral Flow Immunoassay (LFIA) Based Rapid Test Global Market Report 2025

https://thebusinessresearchcompany.com/report/lateral-flow-immunoassay-based-rapid-test-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on:

Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

Analyzing the Growth Rate of the HER2-Negative Breast Cancer Market: What’s the Expected CAGR for the Next Decade?

In recent times, the market size of HER2-negative breast cancer has witnessed considerable growth. The projection suggests an increase from $16.29 billion in 2024 to $17.62 billion in 2025, with a Compound Annual Growth Rate (CAGR) of 8.1%. Factors such as a surge in breast cancer cases, enhanced understanding and knowledge about breast cancer, elevated healthcare expenditure, an aging demographic, and the development of healthcare infrastructures contribute to the growth experienced in the historic period.

Expected to witness robust expansion in the coming years, the HER2-negative breast cancer market is predicted to burgeon to a substantial $23.86 billion by 2029, with a compound annual growth rate (CAGR) of 7.9%. Multiple factors can be credited for this projected growth in the forecast period, encompassing increasing alcohol and tobacco consumption, a rise in unhealthy lifestyle habits, growing prevalence of obesity, and a heightened demand for effectual treatment solutions. As for the significant trends within the forecast period, they comprise advancements in diagnostic technologies, the fusion of targeted therapies, adoption of immunotherapies, FDA approvals, as well as significant technological progress.

How Are Key Drivers in the Industry Acting as Catalysts for the Growth of the HER2-Negative Breast Cancer Market?

The escalating number of breast cancer incidents is set to spur the development of the HER2-negative breast cancer market in the future. Breast cancer is a condition marked by unregulated growth of atypical cells in breast tissues, frequently beginning in ducts or lobules. The growing prevalence of breast cancer is credited to various factors such as higher awareness levels and enhanced screening processes, which allow for more immediate and more consistent detection. HER2-Negative Breast Cancer significantly furthers breast cancer research by offering insights into unique tumor biology and therapeutic approaches, furthering the creation of more precise therapies for patients. For example, as per the Centers for Disease Control and Prevention, a government agency of the US, there were 272,454 fresh cases of breast cancer diagnosed among women in 2021, with 42,211 women losing their lives to the disease in 2022 in the United States. Thus, the increasing occurrence of breast cancer incidents is fueling the expansion of the HER2-negative breast cancer market.

Explore Comprehensive Insights Into The Global HER2-Negative Breast Cancer Market With A Free Sample Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21203&type=smp

What are the leading organizations impacting the HER2-Negative Breast Cancer market’s growth?

Major companies operating in the HER2-negative breast cancer market are Pfizer Inc., Merck & Co. Inc., AbbVie Inc., Bayer AG, Bristol-Myers Squibb Company, Sanofi S.A., AstraZeneca PLC, Novartis International AG, Eli Lilly and Company, Amgen Inc., Daiichi Sankyo Company Limited, Jiangsu Hansoh Pharmaceutical Co. Ltd., BeiGene Ltd., Chipscreen Biosciences Ltd., F. Hoffmann-La Roche Ltd, PharmAbcine Inc., Adagene Inc., H3 Biomedicine Inc., Radius Health Inc., Zenith Epigenetics Ltd.

What Are the Most Prominent Trends Driving Change in the HER2-Negative Breast Cancer Market?

Major players in the HER2-negative breast cancer market are making concerted efforts to obtain regulatory certification in order to launch innovative treatments, extend their product range, and increase their market footprint. These regulatory certifications represent the formal permission given by governmental bodies, which allow firms to sell and distribute medication or treatments once they have proven their safety, effectiveness, and quality. For example, in October 2024, Genentech Inc., a biotechnology firm based in the US, secured FDA approval for its drug named Itovebi (inavolisib), aimed at treating advanced hormone receptor-positive (HR+), HER2-negative breast cancer in patients with a PIK3CA mutation. With this approval, Itovebi can be combined with palbociclib and fulvestrant which significantly enhances the progression-free survival of patients as compared to regular treatments. This updated regimen provides a crucial alternative for patients with limited treatment options, highlighting the significance of biomarker testing to pinpoint those who would gain the most from this specific treatment.

Secure Your Global HER2-Negative Breast Cancer Market Report Now for Fast and Efficient Delivery!

https://www.thebusinessresearchcompany.com/report/her2-negative-breast-cancer-global-market-report

What Are the Core Segments of the HER2-Negative Breast Cancer Market, and How Do They Contribute to Growth?

The HER2-negative breast cancer market covered in this report is segmented –

1) By Treatment Type: Chemotherapy, Hormone Therapy, Targeted Therapy, Immunotherapy

2) By Cancer Stage: Early Stage, Locally Advanced Stage, Metastatic Stage

3) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy

Subsegments:

1) By Chemotherapy: Anthracyclines, Taxanes, Platinum-Based Chemotherapy, Alkylating Agents, Antimetabolites

2) By Hormone Therapy: Selective Estrogen Receptor Modulators (SERMs), Aromatase Inhibitors, Selective Estrogen Receptor Degraders (SERDs)

3) By Targeted Therapy: CDK4/6 Inhibitors, PI3K Inhibitors, PARP Inhibitors

4) By Immunotherapy: Immune Checkpoint Inhibitors, Tumor-Infiltrating Lymphocyte (TIL) Therapy

What Regions Are Leading the Charge in the HER2-Negative Breast Cancer Market?

North America was the largest region in the HER2-negative breast cancer market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the HER2-negative breast cancer market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

How Is the HER2-Negative Breast Cancer Market Categorized and Defined in the Industry?

HER2-negative breast cancer refers to a type of breast cancer where the cancer cells do not have high levels of the HER2 protein, which promotes tumour growth. This type of cancer tends to grow more slowly than HER2-positive breast cancer and is treated with targeted therapies and chemotherapy.

Browse Through More Similar Reports By The Business Research Company:

Anemia and Other Blood Disorder Drugs Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/anemia-and-other-blood-disorder-drugs-global-market-report

Blood Cancer Drugs Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/blood-cancer-drugs-global-market-report

Lateral Flow Immunoassay (LFIA) Based Rapid Test Global Market Report 2025

https://thebusinessresearchcompany.com/report/lateral-flow-immunoassay-based-rapid-test-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: